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Abstract
Introduction Estrogen receptor-alpha (ER-α) and progesterone
receptor (PgR) are consolidated predictors of response to
hormonal therapy (HT). In contrast, little information regarding
the role of estrogen receptor-beta (ER-β) in various breast
cancer risk groups treated with different therapeutic regimens is
available. In particular, there are no data concerning ER-β
distribution within the novel molecular breast cancer subtypes
luminal A (LA) and luminal B (LB), HER2 (HS), and triple-
negative (TN).
Methods We conducted an observational prospective study
using immunohistochemistry to evaluate ER-β expression in 936
breast carcinomas. Associations with conventional
biopathological factors and with molecular subtypes were
analyzed by multiple correspondence analysis (MCA), while
univariate and multivariate Cox regression analysis and
classification and regression tree analysis were applied to
determine the impact of ER-β on disease-free survival in the 728
patients with complete follow-up data.
Results ER-β evenly distributes (55.5%) across the four
molecular breast cancer subtypes, confirming the lack of
correlation between ER-β and classical prognosticators.
However, the relationships among the biopathological factors,
analyzed by MCA, showed that ER-β positivity is located in the
quadrant containing more aggressive phenotypes such as
HER2 and TN or ER-α/PgR/Bcl2- tumors. Kaplan-Meier curves
and Cox regression analysis identified ER-β as a significant
discriminating factor for disease-free survival both in the node-
negative LA (P  = 0.02) subgroup, where it is predictive of
response to HT, and in the node-positive LB (P = 0.04) group,
where, in association with PgR negativity, it conveys a higher
risk of relapse.
Conclusion Our data indicated that, in contrast to node-
negative patients, in node-positive breast cancer patients, ER-β
positivity appears to be a biomarker related to a more aggressive
clinical course. In this context, further investigations are
necessary to better assess the role of the different ER-β
isophorms.
Introduction
It has been shown that longer exposure to estrogen results in
an increased risk of developing breast cancer (BC) and
endogenous estrogens are thought to play a major role in BC
carcinogenesis [1]. Moreover, in BC, estrogen receptor-alpha
(ER-α) and progesterone receptor (PgR) are well-established
biomarkers capable of predicting the likelihood of relapse/pro-
gression in response to endocrine therapy. The identification
AC: anthracycline; BC: breast cancer; C&RT: classification and regression tree; CHT: chemotherapy; CI: confidence interval; DFS: disease-free sur-
vival; EGFR: epidermal growth factor receptor; ER-α: estrogen receptor-alpha; ER-β: estrogen receptor-beta; G: histological grade; HR: hazard ratio; 
HS: HER2; HT: hormonal therapy; IHC: immunohistochemistry; LA: luminal A; LB: luminal B; MCA: multiple correspondence analysis; MoAb: mono-
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of a second type of ER, named estrogen receptor-beta (ER-β)
[2], has prompted the re-evaluation of the model of estrogen
action. To this end, a number of studies have been conducted
retrospectively on selected series of invasive BC to evaluate
the predictive value of ER-β in patients submitted to endocrine
therapy [3]. Unlike ER-α, antiestrogen-occupied ER-β can
activate transcription via nongenomic ER signaling pathways
that involve the activation of cytoplasmic signal transduction
cascades such as the Src/ERK and the PI3K/Akt pathways
[4]. ER-α and ER-β can mediate the biological effects of estro-
gens and antiestrogens by modulating the expression of spe-
cific target genes. At present, however, limited information is
available concerning the differential modulation of gene
expression from either ER-α or ER-β, which share a high
degree of homology in the DNA-binding domain but differ con-
siderably in the NH2-terminal region and, to a lesser extent, in
the ligand-binding domain. Because of this lack of sequence
similarity, it has been suggested that the two receptors might
perform distinct functions [5].
Another important steroid receptor involved in BC progression
is the PgR, which plays a pivotal role in the action of progestins
in target cells and tissues. In invasive BC, PgR expression is
generally regarded as a marker of an intact ER-α signaling
pathway [6]. ER-α and PgR positivities correlate with favora-
ble prognostic features and are predictors of response to hor-
monal therapy (HT), both in the adjuvant setting and in
advanced disease. In contrast, much less is known regarding
the contribution of ER-β to estrogen-driven responses [7] or
its prognostic/predictive role in different early BC risk groups
treated with different chemotherapeutic/hormonal regimens.
This picture has recently been complicated further by the intro-
duction of gene profiling approaches [8] and by the wide-
spread application of a novel BC classification based on the
immunohistochemistry (IHC) phenotypic patterns identified by
a few protein biomarkers, namely ER-α, PgR, HER2, epidermal
growth factor receptor (EGFR), and low-molecular-weight
cytokeratins [9]. According to the expression of such markers,
BC can now be divided into four main subtypes that have dis-
tinct behavior in terms of prognosis and response to therapy
[8]: luminal A (LA) and luminal B (LB), characterized by high
expression of ER-α; triple-negative (TN), characterized by
EGFR and/or by some basal epithelial markers such as cytok-
eratin 5 positivity; and HER2, characterized by the lack of hor-
monal receptors. To date, there are no published data
concerning the distribution of ER-β among these different
molecular subtypes of BC. The aims of the present study were
(a) to prospectively evaluate the relationship between ER-β
and a number of established biopathological parameters in an
observational prospective series of 936 BC patients and (b) to
analyze the impact of ER-β expression on clinical outcome and
on the response to different therapeutic regimens, taking into
account the novel molecular classification.
Materials and methods
Patient characteristics
ER-β was analyzed by IHC in a series of 936 BC patients sub-
jected to breast surgery at the Regina Elena Cancer Institute
(Rome, Italy) between 2001 and 2005. ER-β expression was
routinely determined at the time of surgical treatment along
with other conventional biological factors before any adjuvant
therapy was planned. Patients were subjected to modified rad-
ical mastectomy or breast-conserving surgery (quadrantec-
tomy). Radiotherapy was offered to all patients treated with
quadrantectomy and to patients with lymph node metastases
treated with modified radical mastectomy. Follow-up data
were obtained from hospital charts and by corresponding with
the referring physicians. The clinicopathological characteris-
tics of these patients are summarized in Table 1. Seven hun-
dred sixty-seven of 936 patients with invasive BC with a
median follow-up of 50 months (range 1 to 108 months) were
analyzed for disease-free survival (DFS). The remaining 169
patients (18%) were excluded from DFS analysis since follow-
up for disease recurrence was not available or they were
treated with chemotherapy (CHT) before surgery. The sub-
group analyzed for DFS included 665 (86.7%) invasive ductal
carcinomas, 9 tubular carcinomas (1.2%), 87 invasive lobular
carcinomas (11.3%), and 6 medullary carcinomas (0.8%). In
this series, 58.1% were ER-β+, 69.4% ER-α+, 60.6% PgR+,
and 31.9% HER2+ (19.9% score 2+ and 12% score 3+)
(data not shown). We also studied ER-β distribution in the four
different molecular subtypes: LA (ER-α/PgR+ and HER2-, n =
447), LB (ER-α/PgR+ and HER2+, n = 166), TN (ER-α/PgR-
and HER2-, n = 159), and HS (ER-α/PgR- and HER2+, n =
164). Tumors were graded according to Bloom and Richard-
son and staged according to the Unione Internationale Contre
le Cancer tumor-node-metastasis system criteria and histolog-
ically classified according to the World Health Organization
[10]. The study was reviewed and approved by the ethics
committee of the Regina Elena National Cancer Institute, and
written informed consent was obtained from all patients.
Immunohistochemistry
Formalin-fixed paraffin-embedded breast specimens were cut
on SuperFrost Plus slides (Menzel-Gläser, Braunschweig,
Germany). Antigen retrieval was performed by microwave at
430 W (1 mM citrate buffer, pH 6.0) for two cycles of 10 min-
utes each and one of 5 minutes for anti-ER-β monoclonal anti-
bodies (MoAbs) and by thermostatic bath at 96°C (10 mM/L
citrate buffer, pH 6) for 40 minutes for ER-α, PgR, HER2, p53,
Bcl2, and Ki67. Sections were incubated with the anti-ER-β
MoAbs PPG5/10 (ER-β1, dilution 1:15; GeneTex, Inc., Pro-
dotti Gianni, Milan, Italy) and 14C8 (ER-β total, dilution 1:25;
AbCam, Valter Occhiena s.r.l., Turin, Italy) overnight at 4°C,
with the anti-ER-α MoAb 6F11 (Novocastra, Menarini, Flor-
ence, Italy), the anti-PgR MoAb 1A6 (Menarini), the anti-Ki67
MoAb MIB-1 (Dako, Milan, Italy), the anti-p53 MoAb DO7
(Dako), the anti-Bcl2 MoAb 124 (Dako), and the anti-HER2
polyclonal antibody (A0485; Dako) for 30 minutes at roomAvailable online http://breast-cancer-research.com/content/10/5/R74
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temperature. Positive and negative controls were included for
each antibody and in each batch of staining. The immunoreac-
tions were revealed by a streptavidin-biotin-enhanced peroxi-
dase system (Super Sensitive Link-Label IHC Detection
System; BioGenex, Space, Milan, Italy) using 3-amino-9-ethyl-
carbazole (Dako) as chromogenic substrate. ER-β was
defined as negative (ER-β-) when a weak staining reaction was
observed in less than 20% of carcinoma cell nuclei and as
positive (ER-β+) when a moderate/strong staining reaction
was observed in 20% to 100% of neoplastic cell nuclei. This
cutoff, which was in agreement with Shaaban and colleagues
[11] and Gruvberger-Saal and colleagues [3], was generated
using the classification and regression tree (C&RT) analysis
(see Statistical methods). We introduced three variables
(nodal status, ER-β expression, and relapses) into the model.
The model indicated that, in node-negative patients, the high-
est percentage of relapses occurred when ER-β was positive
in less than 17.5% of neoplastic cells whereas, in node-posi-
tive patients, the highest percentage of relapses occurred
when ER-β was positive in more than 12.5% of neoplastic
cells (Additional file 1). ER-α, PgR, and p53 were considered
positive when greater than 10% of the neoplastic cells
showed a distinct nuclear immunoreactivity whereas Ki67,
based on the median value of our series, was regarded as high
if greater than 15% of the cell nuclei were immunostained.
Bcl2 was recorded as positive when tumor cells exhibited a
strong homogeneous cytoplasmic immunoreaction in more
than 30% of neoplastic cells [12]. HER2 overexpression was
determined as defined in the guide of the HercepTest kit
(Dako): scores of 0 or 1+ were considered negative, 2+ weak
positive, and 3+ strong positive. Evaluation of the immunohis-
tochemical results, blinded to all patient data, was performed
independently and in blinded manner by two investigators (M
Mottolese and FN).
Statistical methods
Correlation among MoAbs anti-ER-β, PPG5/10, and 14C8
was estimated using the kappa test, whereas the correlation
between ER-β and the biopathological characteristic variables
was tested by the Pearson chi-square test. Multiple corre-
spondence analysis (MCA), a descriptive/exploratory tech-
nique designed to analyze simple two-way and multi-way
tables, was used to identify prognostic biological profiles. The
results provide information that is similar in nature to that pro-
duced by factor analysis techniques and make it possible to
explore the structure of categorical variables included in the
table. The most common kind of this type is the two-way fre-
Table 1
Clinicopathological characteristics of 936 invasive breast 
carcinomas
Characteristic Number of cases Percentage
Menopausal status
Premenopause 668 71.4
Postmenopause 268 28.6
Histotype
Tubular carcinoma 14 1.5
Invasive ductal carcinoma 825 88.2
Invasive lobular carcinoma 91 9.7
Other 6 0.6
Histologic grade
Grade 1 151 16.0
Grade 2 493 53.0
Grade 3 292 31.0
Lymph node status
Negative 539 58.0
Positive 397 42.0
Tumor size
T1 579 62.0
T2 290 31.0
T3,4 67 7.0
Estrogen receptor-beta
Negative 416 44.0
Positive 520 56.0
Estrogen receptor-alpha
Negative 278 30.0
Positive 658 70.0
Progesterone receptor
Negative 368 39.0
Positive 568 61.0
HER2
Negative (0/1+) 635 68.0
Positive (2+/3+) 183 32.0
Ki67 expression
Low 529 56.0
High 407 44.0
p53
Negative 714 76.0
Positive 222 23.0
Bcl2
Negative 297 32.0
Positive 639 68.0
Table 1 (Continued)
Clinicopathological characteristics of 936 invasive breast 
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quency cross-tabulation table [13,14]. This representation
aims to visualize the similarities and/or differences of profiles,
simultaneously identifying those dimensions that contain the
majority of the data variability. The positions of the points in the
MCA graph are informative. Categories plotting close to each
other are statistically related and are similar with regard to the
pattern of relative frequencies and this association is statisti-
cally valuable (Lebart's statistic) when the points are located
far from the origin of the graph which represents a mean unin-
formative profile. ER-β, p53, Ki67, Bcl2, hormonal receptors,
or the BC subtypes were the variables of major interest for the
purpose of our study. These factors were introduced in each
analysis as active variables whereas the pathological factors
(tumor size [T], lymph node status [N], and histological grade
[G]) were introduced as supplementary variables. MCA pro-
vides a graphical representation of the active and supplemen-
tary variables projected on a plane formed by axes 1 and 2,
which accounted for 67.6% of total variability, reproducing
quite a significant percentage of the total chi-square value of
the multi-way frequency table. C&RT analysis, a type of deci-
sion tree methodology, is a nonparametric statistical proce-
dure that identifies mutually exclusive and exhaustive
subgroups of a population whose members share common
characteristics that influence the dependent variable of inter-
est. C&RT uses a binary recursive partitioning method that
produces a decision tree that identifies subgroups of patients
with a higher likelihood of being found positive in a test for a
disease state. For analytical purposes, the patients are split
into two groups: a CHT-treated group that included anthracy-
cline (AC) and no AC regimens and an HT-treated group. The
procedure examines all possible independent or splitting vari-
ables and selects the one that produces the most different
binary groups compared with the dependent variable accord-
ing to a predetermined splitting criterion. The parent node,
containing the entire sample, branches into two child nodes
according to the independent variable. Within each of the two
child nodes, the tree-growing methodology continues by
assessing each of the remaining independent variables to
determine which variable results in the best split according to
the chosen criterion. The improvement in prediction was eval-
uated by the Gini coefficient. At the point where no further split
is made, a terminal node is created [15]. For the purpose of
our study, DFS was considered as a measure of outcome.
DFS was calculated from the date of tumor diagnosis to the
date of first recurrence, including contralateral carcinomas,
local relapses, or distant metastases (Additional file 2).
Patients without recurrence were censored at the time of last
follow-up. The DFS curves were estimated by the Kaplan-
Meier product-limit method. The log-rank test was used to
assess differences between subgroups, and significance was
defined as a P value of less than 0.05. A multivariate Cox pro-
portional hazard model was also developed using stepwise
regression (forward selection) with predictive variables that
were significant in the univariate analyses. The enter limit and
remove limit were P = 0.10 and P = 0.15, respectively. The
SPSS (version 14.0) statistical program (SPSS Inc., Chicago,
IL, USA) was used for analyses.
Results
Relationship among estrogen receptor-beta and 
biopathological parameters
In our series of 936 BC patients, 56% of the tumors stained
positive for ER-β1 as detected by MoAb PPG5/10. These
data were also confirmed using the 14C8 MoAb-directed anti-
total ER-β (data not shown) [16], which, in our series, showed
a very good correlation with PPG5/10 (κ = 0.80, 95% CI 69
to 92, P < 0.0001). Results reported hereafter refer to those
obtained with the PPG5/10 MoAb. No significant correlation
was observed between ER-β expression and the other param-
eters analyzed. In contrast, ER-α and PgR were directly related
to each other (P < 0.0001) and to Bcl2 (P < 0.0001) and
inversely correlated with T, G, p53, HER2, and Ki67 (P <
0.0001), as expected from previous reports [11,17]. ER-α, but
not PgR, expression was also significantly associated (P =
0.04) with negative nodal status. The same analysis, per-
formed in the cohort of 767 patients with known follow-up,
gave superimposable results (data not shown). As shown in
Figure 1, 70.3% of cases were ER-α+ and 55.5% were ER-β+.
ER-α and ER-β were coexpressed in 39.0% of cases whereas
31.3% of breast carcinomas were ER-α+  and ER-β-  and
16.5% were ER-α- and ER-β+. When ER-β expression was
analyzed according to the novel BC classification (Figure 2a),
we found that the receptor evenly distributes (P  = 0.99)
among the four molecular subtypes: indeed, ER-β stained pos-
itive in 54.7% of LA, 55.4% of LB, 55.3% of TN, and 56.3%
of HS. In contrast, the percentage of p53 and Ki67+ tumors
significantly increased (P < 0.0001) (Figure 2b,c) and the per-
centage of Bcl2+ tumors significantly decreased moving from
the LA phenotype to LB, TN, and HS (P < 0.0001) (Figure 2d).
Multiple correspondence analysis
As shown in Figure 3, the complex interrelationships among
the biopathological variables considered in our study, either
clustered into phenotypic subtypes (Figure 3a) or considered
individually (Figure 3b), can best be evaluated by using MCA.
Using this analysis, it is possible to visualize the association of
biological factors (ER-α, PgR, HER2, Ki67, p53, and Bcl2)
with ER-β and study their link with conventional pathological
factors (N, G, and T). As shown in Figure 3a, along the first
axis, the test demonstrates the contrast between high Ki67/
p53+ tumors (upper right quadrant) and LA low Ki67/p53-
tumors (lower left quadrant), suggesting that these two groups
represent biopathologically and statistically distinct entities as
their defining parameters appear close to each other directly,
far from the origin, and diagonally opposite. Similarly, the sec-
ond axis clearly differentiates Bcl2+ tumors/LB subtype (upper
left quadrant) from Bcl2- tumors/HER2+ and TN (lower right
quadrant), indicating that these two groups, far from the origin
and diagonally opposite, can be statistically correlated also.
ER-β+ (55.5%), though close to the origin, is located in theAvailable online http://breast-cancer-research.com/content/10/5/R74
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same quadrant (lower right quadrant) as Bcl2-/HER2 subtype/
LB subtype tumors, whereas ER-β- (44.5%) is located in the
opposite upper left quadrant. Figure 3b shows the contrast
between ER-α/PgR/Bcl2- tumors (lower right quadrant) and
ER-α/PgR/Bcl2+ tumors (upper left quadrant), whereas the
second axis clearly differentiates p53+/HER2+/high Ki67
tumors (upper right quadrant) from p53-/HER2-/low Ki67
tumors (lower left quadrant). Consistent with the lack of corre-
lation with other variables and with its even distribution across
different molecular subtypes, ER-β+ (55.2%) or ER-β- (44.8%)
did not discernibly cosegregate with any of the other biopatho-
logical factors considered.
Impact of estrogen receptor-beta expression on disease 
outcome
Classification and regression tree analysis
The prognostic impact of ER-β and other biopathological/clin-
ical parameters on DFS was further assessed in a cohort of
767 patients with complete follow-up data. Thirty-nine patients
who received no systemic adjuvant treatment were excluded
from further analysis. Among the remaining 728 patients, 231
(32%) received exclusive HT, 249 (34%) AC-based CHT, and
248 (34%) non-AC-based CHT. At a median follow-up of 50
months (range 1 to 108 months), a total of 109 out of 728
patients (15%) showed progressive disease (Additional file 2).
C&RT analysis for factors influencing DFS was performed
including all of the biopathological (ER-β, ER-α, PgR, p53,
Ki67, Bcl2, T, N, and G) and clinical (age, menopausal status,
therapy, and DFS) parameters into the model. As graphically
described in Figure 4, the parent node contains the entire
sample of 728 patients. The first splitting node was nodal sta-
Figure 1
ER-alpha (ER-α) and ER-beta (ER-β) distribution in breast carcinomas ER-alpha (ER-α) and ER-beta (ER-β) distribution in breast carcino-
mas. Estrogen receptor-alpha (ER-α) and estrogen receptor-beta (ER-
β) frequency and coexpression in 936 invasive breast carcinomas in an 
observational prospective study.
Figure 2
ER-beta (ER-β), p53, Ki-67 and Bcl2 distribution within BC molecular  subtypes ER-beta (ER-β), p53, Ki-67 and Bcl2 distribution within BC molecu-
lar subtypes. Estrogen receptor-beta (ER-β) evenly distributes (55% 
to 56%, P = 0.99) across the four molecular subtypes (a), whereas the 
percentages of p53 (b) and Ki67+ (c) tumors significantly increased (P 
< 0.0001) and the percentage of Bcl2 significantly decreased (P < 
0.0001) moving from the luminal A (LA) phenotype to luminal B (LB), 
triple-negative (TN), and HER2 (HS) (d).Breast Cancer Research    Vol 10 No 5    Novelli et al.
Page 6 of 12
(page number not for citation purposes)
tus (N). Within the node-negative category (on the left of the
graph), Ki67 was the next splitting node, followed by ER-β sta-
tus and type of therapy received in the high and low Ki67 cat-
egories, respectively; in the HT node, ER-β expression was
associated with a lower number of relapses and better DFS.
Conversely, the node-positive category that splits according
to ER-β expression showed a higher number of relapses
among ER-β+  patients: ER-β+  cases further split by PgR
expression, with lack of PgR correlating with a worse outcome
in terms of DFS.
Univariate and multivariate analysis
We further evaluated the prognostic/predictive impact of ER-
β expression by conventional statistical methods. When the
entire series of 728 cases with complete follow-up data was
analyzed by unadjusted Kaplan-Meier curves, ER-β expression
had no discernible effect on DFS (P = 0.86, Figure 5a). How-
ever, when patients were stratified by nodal status and type of
treatment received, ER-β expression was able to identify sub-
groups of patients at different risk of relapse. Within the node-
negative population, high ER-β expression predicted signifi-
cantly longer DFS in the 210 patients who received HT (P =
0.03, Figure 5b) but not in the group of 240 patients who
received adjuvant CHT (P = 0.55, Figure 5c). Univariate anal-
ysis (Cox model) further confirmed these data, identifying ER-
β+ as a significant predictor of better DFS in the 210 node-
negative patients in the HT group (hazard ratio [HR] 3.033,
confidence interval [CI] 1.077 to 8.539, P = 0.036) but not in
the 240 patients in the CHT group (HR 1.265, CI 0.586 to
2.729,  P  = 0.55). Conversely, and in agreement with the
results obtained by C&RT, ER-β positivity correlated with sig-
nificantly poorer DFS in the 278 node-positive patients (P =
0.04, Figure 5d), the vast majority of whom (246/278, 89%)
received adjuvant CHT (182 AC-based and 64 non-AC-based
CHT following or not by endocrine treatment). In the group of
278 N+ patients, the impact of ER-β+ on adverse clinical out-
come seems to be of prognostic and not of predictive value as
evidenced by Cox model (246 patients CHT-treated HR 1.58,
CI 0.932 to 2.707, P = 0.089; 32 patients HT-treated HR
2.011, CI 0.402 to 10.057, P = 0.39). When the impact of ER-
β expression on DFS was examined in the context of different
BC molecular subtypes, it proved to be of further prognostic
value in LA and LB patients, depending on their nodal status.
Indeed, ER-β positivity identified patients at significantly lower
probability of relapse in node-negative (P = 0.02, Figure 6a)
but not in node-positive (P = 0.66, Figure 6e) LA cases. Con-
versely, ER-β positivity identified patients at significantly higher
probability of relapse in node-positive (P = 0.04, Figure 6f) but
not in node-negative (P = 0.24, Figure 6b) LB cases. No sig-
nificant effect of ER-β expression on DFS was observed in HS
or TN, regardless of nodal status (Figure 6c,d,g,h).
Multivariate analyses
As summarized in Table 2, in the entire series of 728 patients
with complete follow-up data, multivariate analysis revealed
that tumor size (HR 2.51, CI 1.40 to 4.50, P = 0.002), nodal
status (HR 2.44, CI 1.62 to 3.66, P < 0.0001), and Ki67 pro-
liferation index (HR 1.59, CI 1.08 to 2.34, P = 0.02) were inde-
pendent prognostic variables influencing DFS. However, in
Figure 3
Multiple correspondence analysis of the 936 breast carcinomas Multiple correspondence analysis of the 936 breast carcinomas. 
Multiple correspondence analysis of the 936 invasive breast carcino-
mas. Estrogen receptor-beta (ER-β) positivity is located in the quadrant 
containing more aggressive phenotypes such as HER2 (HS) and triple-
negative (TN) (a) or estrogen receptor-alpha, progesterone receptor 
(PgR), and Bcl2-negative tumors (b). LA, luminal A; LB, luminal B; N-, 
node-negative; N+, node-positive.Available online http://breast-cancer-research.com/content/10/5/R74
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Figure 4
Classification and regression tree analysis (C&RT) of the 728 patients with known follow-up Classification and regression tree analysis (C&RT) of the 728 patients with known follow-up. Classification and regression tree analysis of 728 
patients with known follow-up predicts which patient belongs to which specific class (good or poor clinical outcome) on the basis of clinical and bio-
pathological information. Diagram shows diagnostic algorithm generated by AnswerTree 3.1 software, Statistical Package for the Social Sciences 
(SPSS Inc., Chicago, IL, USA). CHT, chemotherapy; ER-β, estrogen receptor-beta; HT, hormonal therapy, N-, node-negative; N+, node-positive; No, 
absence of recurrences; PgR, progesterone receptor; Yes, presence of recurrences.Breast Cancer Research    Vol 10 No 5    Novelli et al.
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the node-positive subgroup, ER-β positivity (HR 1.55, CI 1.93
to 2.57, P = 0.09) emerged as an adverse prognostic factor
for DFS along with tumor size (HR 2.51, CI 1.40 to 4.50, P =
0.002). An opposite effect was observed in the node-negative
subgroup, in which ER-β negativity (HR 1.76, CI 0.95 to 3.24,
P = 0.07) and elevated Ki67 proliferation index (HR 2.16, CI
1.15 to 4.04, P = 0.02) were associated with a poorer disease
outcome.
Discussion
To the best of our knowledge, this is the first study in which the
relationship between ER-β expression, established biopatho-
logical factors, and patient outcome was investigated in an
observational prospective study including a large series of
invasive BC, consecutively accrued over a relatively limited
and recent period of time (2001 to 2005). While ER-α and
PgR expression was significantly associated with HER2, Ki67,
p53, Bcl2, T, N, and G, as one would expect in a representa-
tive well-balanced cohort of unselected patients with early BC,
we observed no significant association between ER-β expres-
sion and the classical biopathological parameters. Our find-
ings, while in agreement with other recently published studies
[3,18], differ from others that have found that ER-β is coex-
pressed with ER-α and PgR and is associated with nodal sta-
tus, grade, proliferation rate [17,19], and HER2
overexpression [20]. Inconsistencies among different studies
are possibly due to different techniques in determining ER-β
expression and lack of validated reagents for IHC. Jarvinen and
colleagues [17] and Umekita and colleagues [20] used the
polyclonal antibody PAI-313 and the MoAb EMR02, respec-
tively, whereas Omoto and colleagues [19] did not specify the
reagents used for their IHC analysis. In our study, we used two
well-characterized anti-ER-β MoAbs, PPG5/10 (ER-β1) and
14C8 (total ER-β), which have previously been shown to be
the best performing antibodies for IHC staining [21] with
superimposable results. Moreover, further discrepancies
could also be related to the selection of different cohorts of
patients. In fact most authors included in their study only retro-
spective series of BC patients dating back to the early 90s,
whereas our series is prospective and includes patients
treated between 2001 and 2005.
We took this kind of analysis one step further and also exam-
ined the distribution of ER-β among different, molecularly dis-
tinct, BC subtypes. Gene expression profiling [8] has, in fact,
led to the identification of subtypes of invasive BC with differ-
Figure 5
Kaplan-Meier estimates of disease-free survival for estrogen receptor-beta (ER-β) status Kaplan-Meier estimates of disease-free survival for estrogen receptor-beta (ER-β) status. Kaplan-Meier estimates of disease-free survival for 
estrogen receptor-beta (ER-β) status in the whole patient group (a), in the 210 node-negative patients treated exclusively with hormonal therapy (b), 
in the 240 node-negative patients subjected to adjuvant chemotherapy followed or not followed by hormonal therapy (c), and in the 246 node-posi-
tive patients subjected to adjuvant chemotherapy followed or not followed by hormonal therapy (d). P values were calculated using the log-rank test.Available online http://breast-cancer-research.com/content/10/5/R74
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ent outcomes, namely LA, LB, TN, and HS. Such classification
has since been translated into routine clinical practice by com-
bining a limited set of markers (ER, PgR, HER2, and basal
cytokeratins) that can be assessed by IHC [9]. We stratified
our 936 BC patients according to these molecular subtypes
and found that ER-β evenly distributes across the four sub-
types, as recently reported by other authors [22]. Such results
were confirmed by MCA [23,24], an alternative method for
Figure 6
Kaplan-Meier estimates of disease-free survival for estrogen receptor-beta (ER-β) status within the molecular subtypes Kaplan-Meier estimates of disease-free survival for estrogen receptor-beta (ER-β) status within the molecular subtypes. Kaplan-Meier esti-
mates of disease-free survival for estrogen receptor-beta (ER-β) status within the molecular subtypes and according to negative (N-) or positive (N+) 
nodal status, respectively, in each subgroup: luminal A (LA) (a, e), luminal B (LB) (b, f), HER2 (HS) (c, g), and triple-negative (TN) (d, h). P values 
were calculated using the log-rank test.Breast Cancer Research    Vol 10 No 5    Novelli et al.
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analyzing multiple categorical variables by graphically visualiz-
ing their interrelationships [25], which showed that ER-β
expression presents a limited dispersion around the origin,
regardless of the method used to classify all of the variables,
that is, by clustering them into discrete subgroups (Figure 3a)
or considering them individually (Figure 3b). These findings
strongly support the lack of correlation between ER-β expres-
sion and the other biopathological parameters considered, fur-
ther validating the hypothesis that ER-β has functions that are
distinct from those of ER-α [26].
The lack of association between ER-β and other classical
prognostic factors makes it an even more attractive candidate
as a prognostic/predictive biomarker. The impact of ER-β
expression on disease outcome (in terms of DFS) was there-
fore studied in a subset of 728 patients with a median follow-
up of 50 months. Using a nonparametric statistical procedure,
C&RT analysis, we were able to identify ER-β as a discriminat-
ing factor in two very interesting subgroups of patients: (a)
node-positive patients, in whom ER-β+ appears to convey a
higher risk of relapse, particularly when coupled with PgR neg-
ativity, and (b) node-negative patients, in whom ER-β+ appears
to predict a favorable response to endocrine therapy. These
results were substantially validated by conventional statistical
procedures, such as Kaplan-Meier analysis of DFS curves and
univariate and multivariate Cox regression analysis, both of
which seem to indicate a divergent role of ER-β expression as
a positive predictive factor in node-negative patients sub-
jected to HT as well as a negative prognosticator in node-pos-
itive patients which does not predict the response to any
therapeutic regimen. Though based on a limited number of
DFS events, the finding of a positive influence of ER-β expres-
sion on the outcome of node-negative BC patients treated
exclusively with HT is supported by several other reports in
which the predictive value of ER-β, detected by mRNA or IHC
staining, was investigated in BC patients undergoing endo-
crine therapy [3,27,28]. In these studies, positive ER-β protein
staining was invariably almost associated with a favorable
response to antiestrogen treatment, consistent with its anti-
proliferative and anti-invasive properties observed in ER-β-
expressing cell lines [29]. Conversely, to the best of our knowl-
edge, this is the first study in which ER-β expression is unex-
pectedly found to be significantly associated with an
unfavorable prognosis in node-positive in an observational
prospective series of BC patients. This is in agreement with
data reported in prostate cancer providing evidence that ER-
β+ tumors had a higher rate of relapse and a small but signifi-
cant decrease in relapse-free survival compared with those in
which ER-β expression had been lost [30]. One likely explana-
tion for our findings in BC is that all of the previous studies that
have measured ER-β i n  B C  h a v e  f o c u s e d  o n  r e s p o n s e  t o
tamoxifen therapy in either adjuvant or metastatic settings
[26,31], while our subset of node-positive BC patients mostly
received adjuvant CHT (with or without ACs). It is interesting
to note that the divergent role of ER-β expression is maintained
even when established pathological factors are clustered
together into distinct molecular subgroups in the context of a
widely used clinical translation of gene expression profiling
studies (LA, LB, TN, and HS). Indeed, depending on nodal sta-
tus, ER-β expression might usefully complement the prognos-
tic assessment of patients in those subgroups (LA and LB)
where further risk stratification by gene expression analysis is
needed to accurately predict prognosis [2,20]. In this context,
ER-β positivity might signal responsiveness to hormonal treat-
ment in node-negative LA patients, on one hand, and a more
aggressive clinical course, requiring ad hoc tailored therapeu-
tic interventions, in node-positive LB patients, on the other,
Table 2
Multivariate analyses of negative prognostic factors for disease-free survival
Disease-free survival
Factors HR (95% CI) P value
All patients (728)
pT stage (3–4 versus 1–2) 2.51 (1.40–4.50) 0.002
pN stage (positive versus negative) 2.44 (1.62–3.66) <0.0001
Ki67 (positive versus negative) 1.59 (1.08–2.34) 0.02
Node-positive patients (278)
pT stage (3–4 versus 1–2) 2.51 (1.40–4.50) 0.002
ER-β (positive versus negative) 1.55 (1.93–2.57) 0.09
Node-negative patients (450)
ER-β (negative versus positive) 1.76 (0.95–3.24) 0.07
Ki67 (positive versus negative) 2.16 (1.15–4.04) 0.02
Cox regression analysis using a forward stepwise procedure (enter limit = 0.10, remove limit = 0.15). CI, confidence interval; ER-β, estrogen 
receptor-beta; HR, hazard ratio; pN, pathological node status; pT, pathological tumor size.Available online http://breast-cancer-research.com/content/10/5/R74
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thereby possibly contributing to the implementation of individ-
ualized therapeutic strategies.
Conclusion
These data support the continued prospective investigation of
ER-β expression in BC patients, adding novel insights into the
complex mechanisms underlying the endocrine pathway.
Future investigations will need to assess the role of ER-β, tak-
ing into account an everchanging scenario in which both ER
biology and endocrine treatment paradigms for BC are rapidly
evolving as highlighted by the discovery of multiple ER-β vari-
ants [32] and by the increasing inclusion of aromatase inhibi-
tors, either upfront or in switching/sequencing strategies, in
the adjuvant treatment plan of patients with early BC [33].
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